Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Identifying conditional synthetic lethal partners of the BAF complex enhanced by PARP or ATR inhibition

EF 2019-20

Résumé
"Our genes need to be tightly regulated to maintain cell function and prevent cells from growing out of control. This is achieved through the actions of a large collection of regulatory proteins, which when mutated lead to cancer development. Recently, there has been increasing awareness of the role of factors that regulate the structure and packaging of DNA. One such factor, the BAF complex, is mutated in approximately 20% of cancers. Mutations have a particularly high prevalence in endometrial and ovarian cancers. Cancer cells contain many mutations, which creates a unique disadvantage compared to normal cells. This weakness is exploited in many of the newest cancer therapies, in what is called a synthetic lethal relationship. A synthetic lethal relationship refers to two genes which individually the cell can survive without, however when both are lost it leads to cell death. We propose to investigate synthetic lethality in cells with a mutated BAF complex in the presence or absence of two new candidate therapies for BAF mutant cancers, PARP inhibitors and ATR inhibitors. We will use the latest gene editing technology to knockout every gene in parallel and identify those which have a synthetic lethal relationship with BAF mutation. We will also determine which genes are synthetic lethal only in the presence of PARP inhibitors or ATR inhibitors. Through this research, we hope to identify factors that can be used to screen patients who are candidates to receive these drugs. Given the high prevalence of BAF mutations in cancer, the genes we identify could also provide exciting opportunities for the development of new treatments for BAF-mutant cancers. "
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428699
Name
Baillie Katherine E
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying conditional synthetic lethal partners of the BAF complex enhanced by PARP or ATR inhibition
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Arid1a; Atr Inhibitors; Baf Complex; Cancer Therapy; Crispr; Parp Inhibitors; Smarca4; Swi/Snf Complex; Synthetic Lethality
Abstract
"Our genes need to be tightly regulated to maintain cell function and prevent cells from growing out of control. This is achieved through the actions of a large collection of regulatory proteins, which when mutated lead to cancer development. Recently, there has been increasing awareness of the role of factors that regulate the structure and packaging of DNA. One such factor, the BAF complex, is mutated in approximately 20% of cancers. Mutations have a particularly high prevalence in endometrial and ovarian cancers. Cancer cells contain many mutations, which creates a unique disadvantage compared to normal cells. This weakness is exploited in many of the newest cancer therapies, in what is called a synthetic lethal relationship. A synthetic lethal relationship refers to two genes which individually the cell can survive without, however when both are lost it leads to cell death. We propose to investigate synthetic lethality in cells with a mutated BAF complex in the presence or absence of two new candidate therapies for BAF mutant cancers, PARP inhibitors and ATR inhibitors. We will use the latest gene editing technology to knockout every gene in parallel and identify those which have a synthetic lethal relationship with BAF mutation. We will also determine which genes are synthetic lethal only in the presence of PARP inhibitors or ATR inhibitors. Through this research, we hope to identify factors that can be used to screen patients who are candidates to receive these drugs. Given the high prevalence of BAF mutations in cancer, the genes we identify could also provide exciting opportunities for the development of new treatments for BAF-mutant cancers. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Baillie, Katherine E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~